Given the success of crizotinib in attaining an impressive response rate of 48% in ROS1- rearranged non-small cell lung cancer [68], similar studies in CCA are warranted to evaluate the potential benefit of targeted therapy in patients with ROS fusions. The gene discussed is ROS1; the disease is cholangiocarcinoma.